Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas
After 10 years one third of the heavily pretreated lymphoma patients who had CAR-T therapy stayed disease free.
Mosunetuzumab Plus Polatuzumab Vedotin in Transplant-Ineligible Refractory/Relapsed Large B-Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
Author(s): Lihua E. Budde, MD, PhD1; Huilai Zhang, MD, PhD2; Won-Seog Kim, MD, PhD3; Dai Maruyama, MD, PhD4; Eduardo M. Rego, MD, PhD5; Lalita Norasetthada, MD6; Huangming Hong, MD7; Muhit Ozcan, MD8; Young-Woo Jeon, MD, PhD9; Danielle Leão Cordeiro de Farias, MD, MSc, MBA10; Laura Maria Fogliatto, MD, PhD11; Astrid Pavlovsky, MD12; Hideki Goto, MD, PhD13; Adam J. Olszewski, MD14; Nikesh Shah, MD15; Bei Hu, MD16; Shen Yin, PhD17; Hao Wu, PhD17; Iris To, PharmD17; Wahib S. Ead, PharmD17; Joan Ashby, MSc17; Martin Janousek, PharmD18; Song Pham, MSc19; Jue Wang, PhD17; Antonia Kwan, MD, PhD17; Connie L. Batlevi, MD, PhD17; Michael C. Wei, MD, PhD17; Jason Westin, MD, MS, FACP, FASCO20;
Source: DOI: 10.1200/JCO-25-01957
Dr. Maen Hussein's Thoughts
Median progression-free survival (PFS) was significantly longer with mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) than with R-GemOx (11.5 months vs 3.8 months). The overall response rate (ORR) was significantly higher with Mosun-Pola compared with R-GemOx (70% vs 40%; P < .0001), with complete response rates of 51% and 24%, respectively. Cytokine release syndrome (CRS) occurred in fewer than 5% of patients.
PURPOSE
Prognosis for patients with refractory/relapsed large B-cell lymphoma (LBCL) considered ineligible for curative-intent therapy is poor. The combination of mosunetuzumab, a T-cell–engaging bispecific antibody, and polatuzumab vedotin, an antibody-drug conjugate (Mosun-Pola), represents a novel fixed-duration outpatient therapy.
METHODS
In the phase III SUNMO trial, patients with refractory/relapsed LBCL who were ineligible for autologous stem-cell transplant were randomly assigned (2:1) to receive Mosun-Pola or rituximab, gemcitabine, and oxaliplatin (R-GemOx). Dual primary end points were centrally assessed overall response rate (ORR) and progression-free survival (PFS). Overall survival was a key secondary end point.
RESULTS
A total of 208 patients were randomly assigned to receive Mosun-Pola (n = 138) or R-GemOx (n = 70). a median follow-up of 23.2 months, the primary analysis of SUNMO demonstrated that the median PFS was significantly longer with Mosun-Pola than with R-GemOx (11.5 months [95% CI, 5.6 to 18] v 3.8 months [95% CI, 2.9 to 4.1]; hazard ratio for progression or death, 0.41 [95% CI, 0.3 to 0.6]; P < .0001). ORR was significantly greater with Mosun-Pola versus R-GemOx (70% v 40%; P < .0001), with complete response rates of 51% and 24%, respectively. In the Mosun-Pola group, the rate of grade ≥2 cytokine release syndrome (CRS) and usage of tocilizumab occurred in
CONCLUSION
Mosun-Pola demonstrated superior efficacy versus R-GemOx, with significant improvements in both ORR and PFS, and infrequent CRS events with a manageable safety profile.
Author Affiliations
1City of Hope, Duarte, CA; 2Tianjin Medical University Cancer Institute, Tianjin, China; 3Samsung Medical Center, Seoul, Republic of Korea; 4Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan; 5Instituto D'Or de Pesquisa e Ensino, São Paulo, Brazil; 6Chiang Mai University, Chiang Mai, Thailand; 7Si Chuan Cancer Hospital, Chengdu, China; 8Ankara University School of Medicine, Ankara, Turkey; 9Yeouido St Mary's Hospital, Seoul, Republic of Korea; 10Hospital Beneficência Portuguesa de São Paulo, São Paulo, Brazil; 11Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil; 12Fundaleu, Buenos Aires, Argentina; 13Department of Hematology, Hokkaido University Hospital, Sapporo, Japan; 14Brown University, Providence, RI; 15Tampa General Hospital Cancer Institute, Tampa, FL; 16Atrium Health Levine Cancer Institute and Wake Forest School of Medicine, Charlotte, NC; 17Genentech, Inc, South San Francisco, CA; 18F. Hoffmann-La Roche Ltd, Basel, Switzerland; 19Hoffmann-La Roche Ltd, Mississauga, ON, Canada; 20MD Anderson Cancer Center, Houston, TXRelated Articles
Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial
Progression-free survival was improved in the tafa-len-R-CHOP group vs the R-CHOP with 2-year progression-free survival rates of 71·1vs 62·9% toxicity was higher with tafa-len-R-CHOP with a higher rate of fatal treatment-emergent adverse events, but more overall deaths the RCHOP arm. It is early to add Len taf because of toxicity esp with OS survival and deep response data being immature.
BRUIN CLL-313: Randomized Phase III Trial of Pirtobrutinib Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib demonstrated superiority over bendamustine rituximab in IRC assessed progression free survival (PFS) in treatment naïve CLL/SLL, with a 24 month PFS rate of 93.4% versus 70.7%. Overall survival trends favored pirtobrutinib, despite the study design allowing for crossover. Who would have thought this was coming????
Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Another update demonstrated the superiority of polatuzumab vedotin plus R-CHOP (Pola-R-CHOP) over R-CHOP alone, with improved progression-free survival (PFS) (64% vs 59%). Overall survival (OS) was not statistically significant; however, the hazard ratio was 0.85, with greater benefit observed in high-risk patients.
Remission Assessment by Circulating Tumor DNA in Large B-Cell Lymphoma
Minimal residual disease (MRD) testing after two cycles of therapy and at the end of treatment predicted 2-year progression-free survival (PFS) (96% in MRD-negative patients vs 67% in MRD-positive patients). MRD status was more predictive of treatment outcomes than radiographic imaging in this patient population.